NOVARTIS AG-REG (NOT.DE) Stock Price & Overview

FRA:NOT • CH0012005267

Current stock price

129.6 EUR
-1.12 (-0.86%)
Last:

The current stock price of NOT.DE is 129.6 EUR. Today NOT.DE is down by -0.86%. In the past month the price decreased by -9.95%.

NOT.DE Key Statistics

1-Month Range124.76 - 143.64
Current NOT.DE stock price positioned within its 1-month range.
Market Cap
248.675B
P/E
16.66
Fwd P/E
16.54
EPS (TTM)
7.78
Dividend Yield
3.10%

NOT.DE Stock Performance

Today
-0.86%
1 Week
+2.35%
1 Month
-9.95%
3 Months
+9.26%
Longer-term
6 Months +23.05%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

NOT.DE Stock Chart

NOVARTIS AG-REG / NOT Daily stock chart

NOT.DE Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to NOT.DE.


Chartmill TA Rating
Chartmill Setup Rating

NOT.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NOT.DE. Both the health and profitability get an excellent rating, making NOT.DE a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NOT.DE Earnings

On February 4, 2026 NOT.DE reported an EPS of 2.03 and a revenue of 13.34B. The company missed EPS expectations (-0.17% surprise) and missed revenue expectations (-4.89% surprise).

Next Earnings DateApr 27, 2026
Last Earnings DateFeb 4, 2026
PeriodQ4 / 2025
EPS Reported$2.03
Revenue Reported13.336B
EPS Surprise -0.17%
Revenue Surprise -4.89%

NOT.DE Forecast & Estimates

34 analysts have analysed NOT.DE and the average price target is 132.51 EUR. This implies a price increase of 2.24% is expected in the next year compared to the current price of 129.6.

For the next year, analysts expect an EPS growth of 0.69% and a revenue growth 2.75% for NOT.DE


Analysts
Analysts70.59
Price Target132.51 (2.25%)
EPS Next Y0.69%
Revenue Next Year2.75%

NOT.DE Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

NOT.DE Financial Highlights

Over the last trailing twelve months NOT.DE reported a non-GAAP Earnings per Share(EPS) of 7.78. The EPS increased by 14.98% compared to the year before.


Income Statements
Revenue(TTM)56.33B
Net Income(TTM)13.98B
Industry RankSector Rank
PM (TTM) 24.83%
ROA 12.6%
ROE 30.31%
Debt/Equity 0.64
Chartmill High Growth Momentum
EPS Q2Q%2.53%
Sales Q2Q%1.39%
EPS 1Y (TTM)14.98%
Revenue 1Y (TTM)8.91%

NOT.DE Ownership

Ownership
Inst Owners41.7%
Shares1.92B
Float1.69B
Ins Owners0.03%
Short Float %N/A
Short RatioN/A

About NOT.DE

Company Profile

NOT logo image Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Company Info

IPO: 2001-05-07

NOVARTIS AG-REG

Lichtstrasse 35

Basel BASEL-STADT CH

Employees: 75267

NOT Company Website

NOT Investor Relations

Phone: 41613241111

NOVARTIS AG-REG / NOT.DE FAQ

Can you describe the business of NOVARTIS AG-REG?

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.


What is the stock price of NOVARTIS AG-REG today?

The current stock price of NOT.DE is 129.6 EUR. The price decreased by -0.86% in the last trading session.


Does NOT stock pay dividends?

NOVARTIS AG-REG (NOT.DE) has a dividend yield of 3.1%. The yearly dividend amount is currently 3.49.


What is the ChartMill technical and fundamental rating of NOT stock?

NOT.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


What is the Price/Earnings (PE) ratio of NOVARTIS AG-REG (NOT.DE)?

The PE ratio for NOVARTIS AG-REG (NOT.DE) is 16.66. This is based on the reported non-GAAP earnings per share of 7.78 and the current share price of 129.6 EUR.


What is the next earnings date for NOT stock?

NOVARTIS AG-REG (NOT.DE) will report earnings on 2026-04-27.